文献速递胸部肿瘤头颈与中枢神经肿瘤

HERTHENA-Lung01:Patritumab Deruxtecan(HER3-DXd)在EGFR突变非小细胞肺癌患者经EGFR酪氨酸激酶抑制剂和铂类化疗后的II期试验

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
PubMed 文献 · J Clin Oncol · 2023-09-10

这项II期试验评估HER3-DXd在既往接受EGFR TKI和铂类化疗后进展的EGFR突变晚期NSCLC患者中的疗效与安全性。225例患者接受HER3-DXd 5.6 mg/kg每3周一次,确认客观缓解率为29.8%,中位缓解持续时间6.4个月,中位无进展生存期5.5个月,中位总生存期11.9个月。在30例基线未放疗脑转移患者中,中枢神经系统确认客观缓解率为33.3%。

要点

  • HER3-DXd 5.6 mg/kg每3周一次在EGFR突变NSCLC经EGFR TKI和铂类化疗后显示确认ORR 29.8%。
  • 中位缓解持续时间6.4个月,中位PFS 5.5个月,中位OS 11.9个月。
  • 基线未放疗脑转移患者(n=30)中枢神经系统确认ORR为33.3%。

核心结论

  • 在EGFR突变NSCLC患者经EGFR TKI治疗和铂类化疗后肿瘤进展的情况下,HER3-DXd每3周一次显示出具有临床意义的疗效和持久缓解,包括中枢神经系统转移。

研究设计与样本

  • 这是一项II期研究(ClinicalTrials.gov标识符:NCT04619004),旨在评估HER3-DXd在既往接受EGFR TKI治疗和铂类化疗的晚期EGFR突变NSCLC患者中的疗效。
  • 患者接受HER3-DXd 5.6 mg/kg静脉给药每3周一次或递增方案(3.2→4.8→6.4 mg/kg)。
  • 主要终点为盲法独立中心审查(BICR)根据RECIST 1.1确认的客观缓解率(ORR),零假设为26.4%(基于历史数据)。
  • 递增组基于I期U31402-A-U102试验数据的预设获益-风险评估提前关闭入组。
  • 共有225例患者接受HER3-DXd 5.6 mg/kg每3周一次治疗。

主要发现

  • 截至2023年5月18日,中位研究持续时间为18.9个月(范围14.9-27.5个月)。
  • BICR确认的ORR为29.8%(95% CI 23.9至36.2);中位缓解持续时间6.4个月;中位无进展生存期5.5个月;中位总生存期11.9个月。
  • 既往接受奥希替尼和铂类化疗的患者亚组结局相似。
  • 在基线未放疗脑转移患者(n=30)中,BICR根据CNS RECIST确认的中枢神经系统ORR为33.3%(95% CI 17.3至52.8)。
  • 安全性特征(NCI CTCAE v5.0)可控且可耐受,与既往观察一致。

关键数值与推荐

  • 主要终点确认ORR为29.8%(95% CI 23.9至36.2),高于零假设26.4%。
  • 中位缓解持续时间6.4个月,中位无进展生存期5.5个月,中位总生存期11.9个月。
  • 基线未放疗脑转移患者(n=30)中枢神经系统确认ORR为33.3%(95% CI 17.3至52.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 递增组基于I期U31402-A-U102试验数据的预设获益-风险评估提前关闭入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). METHODS: This phase II study (ClinicalTrials.gov identifier: NCT04619004) was designed to evaluate HER3-DXd in patients with advanced EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy (PBC). Patients received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks or an uptitration regimen (3.2 → 4.8 → 6.4 mg/kg). The primary end point was confirmed objective response rate (ORR; RECIST 1.1) by blinded independent central review (BICR), with a null hypothesis of 26.4% on the basis of historical data. RESULTS: Enrollment into the uptitration arm closed early on the basis of a prespecified benefit-risk assessment of data from the phase I U31402-A-U102 trial. In total, 225 patients received HER3-DXd 5.6 mg/kg once every 3 weeks. As of May 18, 2023, median study duration was 18.9 (range, 14.9-27.5) months. Confirmed ORR by BICR was 29.8% (95% CI, 23.9 to 36.2); median duration of response, 6.4 months; median progression-free survival, 5.5 months; and median overall survival, 11.9 months. The subgroup of patients with previous osimertinib and PBC had similar outcomes. Efficacy was observed across a broad range of pretreatment tumor HER3 membrane expression levels and across diverse mechanisms of EGFR TKI resistance. In patients with nonirradiated brain metastases at baseline (n = 30), the confirmed CNS ORR by BICR per CNS RECIST was 33.3% (95% CI, 17.3 to 52.8). The safety profile (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) was manageable and tolerable, consistent with previous observations. CONCLUSION: After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR-mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023. PMID: 37689979. doi:10.1200/JCO.23.01476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。